Giorgi-Renault S, Renault J, Gebel-Servolles P, Baron M, Paoletti C, Cros S, Bissery M C, Lavelle F, Atassi G
Département de Chimie Organique, Faculté des Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.
J Med Chem. 1991 Jan;34(1):38-46. doi: 10.1021/jm00105a007.
A series of heterocyclic quinones, 6-substituted and 6,7-disubstituted 4-(alkylamino)-5,8-quinazolinediones, have been synthesized in order to evaluate their in vitro cytotoxicity on L1210 leukemia cells. Among 14 derivatives that have been prepared and studied for the structure-activity relationship, the most potent cytotoxic compound on L1210 leukemia cells was the 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione (24). This compound has been tested with the use of a cell-image processor on MCF-7 human mammary and HBL human melanoma cell lines. The results show that compound 24 influences cell proliferation and blocks both cells lines in the S phase. In vivo antineoplastic activity of compound 24 has been demonstrated on a broad spectrum of murine experimental models, but it was found highly toxic and produced long-delayed deaths.
为了评估一系列杂环醌类化合物,即6-取代和6,7-二取代的4-(烷基氨基)-5,8-喹唑啉二酮对L1210白血病细胞的体外细胞毒性,已合成了这些化合物。在已制备并研究其构效关系的14种衍生物中,对L1210白血病细胞毒性最强的化合物是6,7-双(1-氮丙啶基)-4-[[3-(N,N-二甲基氨基)丙基]氨基]-5,8-喹唑啉二酮(24)。该化合物已通过细胞图像处理器在MCF-7人乳腺细胞系和HBL人黑色素瘤细胞系上进行了测试。结果表明,化合物24影响细胞增殖,并使两个细胞系都停滞在S期。化合物24在多种小鼠实验模型上已显示出体内抗肿瘤活性,但发现其毒性很高,并导致长时间延迟死亡。